295 Pangyo-ro, Bundang-gu, 13488 Seongnam-si, Gyeonggi-do
Korea, Republic
Telephone +82 2 21579833
Fax +82 2 21579062
hongsik.kim@samyang.com
http://www.samyangbiopharm.com/eng
Product Categories
01 Electromedical equipment / Medical Technology
01.08 Surgery and Endoscopy
01.08.02 Surgical instruments and products
MEDICA 2017
Surgical instruments and products
Monolene®
Proflex® Mesh
2 Products
01 Electromedical equipment / Medical Technology
01.08 Surgery and Endoscopy
01.08.02 Surgical instruments and products
01.08.02.08 Surgical suture materials
MEDICA 2017
Surgical suture materials
Trisorb® / Trisorb®Ⅱ
Trisorb® Plus
Neosorb® Loop / Monosorb® Loop
3 Products
ad: contact information
Company
Company details
Samyang group has identified healthcare as its key strategic business focus for the 21st century.
The Samyang Biopharm is engaged in research and development of innovative technology platforms for drug delivery and
novel application of its expertise in biopolymers for developing biomedical devices.
The Biomedical R&D Center aims to lead the DDS(Drug Delivery System) research sector worldwide. Based on our accumulated experience in synthetic synthetic resins and fine chemicals, we are continuing to closely cooperate with overseas partners and developing innovative DDS.
Thanks to Samyang Discovery Center, which was established in Seongnam Pangyo Techno Valley in April 2016, Samyang Biopharm will confirm its position as a specialized pharmaceutical company with improved R&D capability and become an R&D center that leads the sustainable growth and development of the company.
Samyang Biopharm set ‘Value Creative Pharma Company’ as its vision for 2020, which illustrates its goal to become a company that provides ‘Life’s Ingredients.
The Samyang Biopharm’s pharmaceutical plant was established in 1997 to produce premium quality active pharmaceutical ingredients(APIs) using novel plant cell culture and semisynthetic technologies. The plant was equipped in 2007 with
modern injection filling line which is dedicated to produce anti-cancer injectables.
The Biopharmaceutical plant is Korean GMP compliant and passed inspection of German and Japanese health agencies.
ad: contact information